Latest Administration News

Ansell Limited has announced a USD 0.222 per share dividend for the six months ending December 2024, payable in March 2025 with a full dividend reinvestment plan available.

Ansell Limited delivered a robust FY25 half-year performance, marked by double-digit sales and earnings growth, successful KBU acquisition integration, and an upward revision of adjusted EPS guidance.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Blackstone Minerals is set to merge with IDM International, combining expertise and local presence to advance exploration of the world-class Mankayan copper-gold porphyry project in the Philippines.

Loyal Lithium unveils a strategic pivot to broaden its North American lithium and battery technology portfolio, leveraging new US energy policies and $5.5 million in funding to capitalize on the continent’s evolving energy grid demands.

Podium Minerals has completed its acquisition of EV Nickel’s assets, consolidating key nickel and PGM projects and welcoming industry giant Johnson Matthey as a 16.25% shareholder.

InFocus Group Holdings has completed its acquisition of Bangkok-based Prodigy9, enhancing its software engineering and data analytics capabilities while aiming for rapid cash flow generation.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

A1 Investments & Resources Ltd reported a modest cash outflow for the December quarter while actively pursuing acquisition opportunities backed by secured funding. The company aims to finalize a deal soon, contingent on shareholder and regulatory approvals.